Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cabotegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 17/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.85 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cabotegravir SCHEMBL22584741 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL93097 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL18253200 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL18881147 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL81491 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL787358 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL82803 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL10002356 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL19987969 | 0.99 | SLC22A2 (0.83) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL82533 | 0.99 | SLC22A2 (0.83) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| CN-115916175-A | Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses | 南方研究院 | 2023-04-04 | — | — | CN | claimed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| EP-4125845-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | Southern Research Institute (US) | 2023-02-08 | — | — | EP | claimed |
| EP-3166607-B1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2022-08-31 | — | — | EP | claimed |
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | claimed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-11259956-B2 | Combination therapy intravaginal rings | INTERNATIONAL PARTNERSHIP FOR MICROBICIDES, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3397639-B1 | FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | disclosed |
| US-11234985-B2 | Antiviral therapy | VIIV HEALTHCARE COMPANY | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | IRF3, STING1, MAVS | SLC22A2 3484/4885CYP3A4 3581/4885TMEM97 2497/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | SLC22A2 3222/4885CYP3A4 4764/4885TMEM97 2369/4885 |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | SLC22A2 3890/4885CYP3A4 1779/4885TMEM97 2660/4885 |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | SLC22A2 1927/4885CYP3A4 2399/4885TMEM97 122/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | SLC22A2 1927/4885CYP3A4 2399/4885TMEM97 122/4885 |
| US-11259956-B2 | Combination therapy intravaginal rings | QDPR, DUT, DPYD | SLC22A2 4496/4885CYP3A4 173/4885TMEM97 1999/4885 |
| US-11234985-B2 | Antiviral therapy | SAMHD1, EIF2AK2, MAVS | SLC22A2 3994/4885CYP3A4 1718/4885TMEM97 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.